Eli Lilly & Co (NYSE:LLY) stock is up 1.1% premarket, after the drugmaker's next-generation weight-loss drug retatrutide delivered an impressive 28.7% weight loss in a phase 3 trial, also reducing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback